Polydatin Injectable (HW6) for Shock Treatment

Status Not yet recruiting

Clinical Trial Summary

HW6 can prolong animal's survival time and increase the survival rate. HW6 enhances cardiac function, improves microcirculation, and increases blood pressure and pulse pressure, and improves blood perfusion of important organs; HW6's anti-shock activity comes from a combined multiple target pharmacological effects.

Based on a completed phase II trial conducted in China, HW6 can effectively treatment shock patient.

This is a phase II clinical study to further evaluate the efficacy and safety of Polydatin Injectable 100mg/5mL/via (HW6) in the treatment of shock in the United States. Patients with traumatic/hemorrhagic shock or septic shock admitted to the emergency room or ICU with systolic blood pressure < 90mmHg, or is on vasopressor(s) for systolic blood pressure stabilization, regardless the types of completed, on-going, or projected Standard of Care or surgery will be recruited to participant in the trial. A total of 120 patients with traumatic/hemorrhagic shock and 120 patients with septic shock will be enrolled. For each type of shock, sixty patients each will be in test group and control group. Both adult males and females aged 18-80 years are eligible. The primary clinical endpoint is the time length (TL) between the start of HW6 administration to the onset of the first treatment success, that is: the systolic blood pressure is stabilized at ≥90mmHg and MAP≥65mmHg for 1 hour without the use of vasopressors. Several secondary endpoints and biomarkers will be measured.

Efficacy data will be compared using group t-test or Wilcoxon log-rank test between treatment groups and placebo groups. Safety data will also be reported accordingly.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01780129
Study type	Interventional
Source	Neptunus Pharmaceuticals Inc.
Contact	SUN Henry, PHD
Phone	(301) 956-9607
Email	henrysun@neptunus.com
Status	Not yet recruiting
Phase	Phase 2
Start date	February 2013
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03592693` - Vitamin C, Hydrocortisone and Thiamine for Septic Shock	Phase 2
Terminated	`NCT01639664` - COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2	N/A
Withdrawn	`NCT01601938` - Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients	Phase 2
Recruiting	`NCT00335907` - Protocol-driven Hemodynamic Support for Patients With Septic Shock	N/A
Completed	`NCT00000574` - Ibuprofen in Sepsis Study	Phase 3
Recruiting	`NCT04910841` - Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine	N/A
Active, not recruiting	`NCT04079829` - Postoperative Respiratory Abnormalities
Recruiting	`NCT04569942` - Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis	Phase 3
Recruiting	`NCT04934943` - "Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
Completed	`NCT01310790` - Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock	Phase 4
Completed	`NCT00241228` - Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)	N/A
Completed	`NCT00046072` - A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis	Phase 2
Withdrawn	`NCT03122678` - Thiamine Supplementation in Patients With Septic Shock	Phase 1
Recruiting	`NCT06155812` - Multimodal Vasopressor Strategy in Septic Shock	Phase 2/Phase 3
Completed	`NCT04178148` - Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock	N/A
Completed	`NCT01453270` - Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial	N/A
Recruiting	`NCT04576819` - Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
Active, not recruiting	`NCT04055909` - Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock	Phase 2
Suspended	`NCT03193164` - Neuromuscular Electrical Stimulation and Septic Shock	N/A
Completed	`NCT04647552` - Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Polydatin Injectable (HW6) for Shock Treatment — PIST

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms